Malignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resections

被引:129
作者
Boninsegna, Letizia [1 ,4 ]
Panzuto, Francesco [2 ]
Partelli, Stefano [1 ,4 ]
Capelli, Paola [3 ]
Delle Fave, Gianfranco [2 ]
Bettini, Rossella [4 ]
Pederzoli, Paolo [1 ]
Scarpa, Aldo [3 ,5 ]
Falconi, Massimo [1 ]
机构
[1] Univ Verona, Dept Surg, I-37100 Verona, Italy
[2] Univ Roma La Sapienza, Dept Gastroenterol, Rome, Italy
[3] Univ Verona, Dept Pathol, I-37100 Verona, Italy
[4] Osped Sacro Cuore, Dept Surg, Verona, Italy
[5] ARC NET Ctr Appl Res Canc, Verona, Italy
关键词
Pancreatic neuroendocrine tumour; Prognosis; Recurrence; Surgery; Lymph node ratio; Ki67; ISLET-CELL-CARCINOMA; PROGNOSTIC-FACTORS; ENDOCRINE TUMORS; SURVIVAL; CHEMOTHERAPY; MANAGEMENT; DIAGNOSIS; RELEVANCE; SERIES;
D O I
10.1016/j.ejca.2011.10.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Malignant pancreatic neuroendocrine tumours (PNENs) are generally associated with a good prognosis after radical resection. In other pancreatic malignancies predictors of recurrence and the role of lymph node ratio (LNR) are well known, but both have been scarcely investigated for malignant PNETs. Methods: The prospective database from the surgical Department of Verona University was queried. Clinical and pathological data of all patients with resected malignant PNET between 1990 and 2008 were reviewed. Univariate and multivariate analysis were performed. Results: Fifty-seven patients (male/female ratio = 1) with a median age of 58 years (33-78) entered in the study. Twenty-nine (51%) patients underwent pancreaticoduodenectomy and 28 (49%) distal pancreatectomy. Postoperative mortality was nil with a 37% morbidity rate. There were 36 (63%) patients with lymph node metastases (N1). Of these, 23 (64%) had a lymph node ratio (LNR) >0 and <= 0.20 and 13 (36%) had a LNR >0.20. The median overall survival and the median disease free survival (DFS) were 190 and 80 months, respectively. Recurrent disease was identified in 24 patients (42%) with a 2 and 5-year DFS rate of 82% and 49%, respectively. On multivariate analysis, LNR >0.20 (HR = 2.75) and a value of Ki67 >5% (HR = 3.39) were significant predictors of recurrence (P < 0.02). Conclusions: After resection for malignant PNETs, LNR and a Ki67 >5% are the most powerful predictors of recurrence. The presence of these factors should be considered for addressing patients to adjuvant treatment in future clinical trials. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1608 / 1615
页数:8
相关论文
共 33 条
  • [1] *AM JOINT COMM CAN, 2002, AJCC CANC STAG MAN, P157
  • [2] Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours
    Bettini, R.
    Boninsegna, L.
    Mantovani, W.
    Capelli, P.
    Bassi, C.
    Pederzoli, P.
    Delle Fave, G. F.
    Panzuto, F.
    Scarpa, A.
    Falconi, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (05) : 903 - 908
  • [3] Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors - Analysis of 3851 patients
    Bilimoria, Karl Y.
    Talamonti, Mark S.
    Tomlinson, James S.
    Stewart, Andrew K.
    Winchester, David P.
    Ko, Clifford Y.
    Bentrem, David J.
    [J]. ANNALS OF SURGERY, 2008, 247 (03) : 490 - 500
  • [4] Bosman, 2010, WHO Classification of Tumours of the Digestive System IARC, 2010
  • [5] Prognostic Relevance of Lymph Node Ratio and Number of Resected Nodes after Curative Resection of Ampulla of Vater Carcinoma
    Falconi, Massimo
    Crippa, Stefano
    Dominguez, Ismael
    Barugola, Giuliano
    Capelli, Paola
    Marcucci, Stefano
    Beghelli, Stefania
    Scarpa, Aldo
    Bassi, Claudio
    Pederzoli, Paolo
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (11) : 3178 - 3186
  • [6] Fischer L, 2008, BRIT J SURG, V95, P627, DOI 10.1002/bjs.6051
  • [7] Gullo L, 2003, AM J GASTROENTEROL, V98, P2435
  • [8] Prognostic factors in pancreatic endocrine neoplasms: An analysis of 136 cases with a proposal for low-grade and intermediate-grade groups
    Hochwald, SN
    Zee, S
    Conlon, KC
    Colleoni, R
    Louie, O
    Brennan, MF
    Klimstra, DS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2633 - 2642
  • [9] The diagnosis and medical management of advanced neuroendocrine tumors
    Kaltsas, GA
    Besser, GM
    Grossman, AB
    [J]. ENDOCRINE REVIEWS, 2004, 25 (03) : 458 - 511
  • [10] Advances in the treatment of neuroendocrine tumors
    Kulke M.
    [J]. Current Treatment Options in Oncology, 2005, 6 (5) : 397 - 409